Global Targeted Drugs for Multiple Sclerosis 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11247058

Publication Date:

November 14, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Targeted Drugs for Multiple Sclerosis market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (publisher)' newest research report, the 鈥淭argeted Drugs for Multiple Sclerosis Industry Forecast鈥� looks at past sales and reviews total world Targeted Drugs for Multiple Sclerosis sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Multiple Sclerosis sales for 2023 through 2029. With Targeted Drugs for Multiple Sclerosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Multiple Sclerosis industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Multiple Sclerosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Multiple Sclerosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Targeted Drugs for Multiple Sclerosis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Multiple Sclerosis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Multiple Sclerosis.
United States market for Targeted Drugs for Multiple Sclerosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Targeted Drugs for Multiple Sclerosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Targeted Drugs for Multiple Sclerosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Targeted Drugs for Multiple Sclerosis players cover Biogen, NOVARTIS, Bristol-Myers Squibb, Janssen, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Multiple Sclerosis market by product type, application, key players and key regions and countries.
Segmentation by Type:
Injection
Oral
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Injection
Oral
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
NOVARTIS
Bristol-Myers Squibb
Janssen
Sanofi
Roche

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Targeted Drugs for Multiple Sclerosis 麻豆原创 Size 2019-2030
2.1.2 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Targeted Drugs for Multiple Sclerosis by Country/Region, 2019, 2023 & 2030
2.2 Targeted Drugs for Multiple Sclerosis Segment by Type
2.2.1 Injection
2.2.2 Oral
2.3 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Type
2.3.1 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Targeted Drugs for Multiple Sclerosis 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Targeted Drugs for Multiple Sclerosis Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Application
2.5.1 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Targeted Drugs for Multiple Sclerosis 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Player
3.1 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Targeted Drugs for Multiple Sclerosis Revenue by Player (2019-2024)
3.1.2 Global Targeted Drugs for Multiple Sclerosis Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Targeted Drugs for Multiple Sclerosis Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Targeted Drugs for Multiple Sclerosis by Region
4.1 Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Region (2019-2024)
4.2 Global Targeted Drugs for Multiple Sclerosis Annual Revenue by Country/Region (2019-2024)
4.3 Americas Targeted Drugs for Multiple Sclerosis 麻豆原创 Size Growth (2019-2024)
4.4 APAC Targeted Drugs for Multiple Sclerosis 麻豆原创 Size Growth (2019-2024)
4.5 Europe Targeted Drugs for Multiple Sclerosis 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Targeted Drugs for Multiple Sclerosis 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Country (2019-2024)
5.2 Americas Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Type (2019-2024)
5.3 Americas Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Region (2019-2024)
6.2 APAC Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Type (2019-2024)
6.3 APAC Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Country (2019-2024)
7.2 Europe Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Type (2019-2024)
7.3 Europe Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Targeted Drugs for Multiple Sclerosis by Region (2019-2024)
8.2 Middle East & Africa Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Targeted Drugs for Multiple Sclerosis 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Targeted Drugs for Multiple Sclerosis 麻豆原创 Forecast
10.1 Global Targeted Drugs for Multiple Sclerosis Forecast by Region (2025-2030)
10.1.1 Global Targeted Drugs for Multiple Sclerosis Forecast by Region (2025-2030)
10.1.2 Americas Targeted Drugs for Multiple Sclerosis Forecast
10.1.3 APAC Targeted Drugs for Multiple Sclerosis Forecast
10.1.4 Europe Targeted Drugs for Multiple Sclerosis Forecast
10.1.5 Middle East & Africa Targeted Drugs for Multiple Sclerosis Forecast
10.2 Americas Targeted Drugs for Multiple Sclerosis Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.2.2 Canada 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.2.3 Mexico 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.2.4 Brazil 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.3 APAC Targeted Drugs for Multiple Sclerosis Forecast by Region (2025-2030)
10.3.1 China Targeted Drugs for Multiple Sclerosis 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.3.3 Korea 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.3.4 Southeast Asia 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.3.5 India 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.3.6 Australia 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.4 Europe Targeted Drugs for Multiple Sclerosis Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.4.2 France 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.4.3 UK 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.4.4 Italy 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.4.5 Russia 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.5 Middle East & Africa Targeted Drugs for Multiple Sclerosis Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.5.2 South Africa 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.5.3 Israel 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.5.4 Turkey 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
10.6 Global Targeted Drugs for Multiple Sclerosis Forecast by Type (2025-2030)
10.7 Global Targeted Drugs for Multiple Sclerosis Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Targeted Drugs for Multiple Sclerosis Forecast
11 Key Players Analysis
11.1 Biogen
11.1.1 Biogen Company Information
11.1.2 Biogen Targeted Drugs for Multiple Sclerosis Product Offered
11.1.3 Biogen Targeted Drugs for Multiple Sclerosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Biogen Main Business Overview
11.1.5 Biogen Latest Developments
11.2 NOVARTIS
11.2.1 NOVARTIS Company Information
11.2.2 NOVARTIS Targeted Drugs for Multiple Sclerosis Product Offered
11.2.3 NOVARTIS Targeted Drugs for Multiple Sclerosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 NOVARTIS Main Business Overview
11.2.5 NOVARTIS Latest Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Information
11.3.2 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Product Offered
11.3.3 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Bristol-Myers Squibb Main Business Overview
11.3.5 Bristol-Myers Squibb Latest Developments
11.4 Janssen
11.4.1 Janssen Company Information
11.4.2 Janssen Targeted Drugs for Multiple Sclerosis Product Offered
11.4.3 Janssen Targeted Drugs for Multiple Sclerosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Janssen Main Business Overview
11.4.5 Janssen Latest Developments
11.5 Sanofi
11.5.1 Sanofi Company Information
11.5.2 Sanofi Targeted Drugs for Multiple Sclerosis Product Offered
11.5.3 Sanofi Targeted Drugs for Multiple Sclerosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Sanofi Main Business Overview
11.5.5 Sanofi Latest Developments
11.6 Roche
11.6.1 Roche Company Information
11.6.2 Roche Targeted Drugs for Multiple Sclerosis Product Offered
11.6.3 Roche Targeted Drugs for Multiple Sclerosis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Roche Main Business Overview
11.6.5 Roche Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.